Dr. Huiqiang Huang: Advances in Clinical Immunotherapy for Lymphoma, Highlighting PD-1/PD-L1 Antibody Combination Therapies

Dr. Huiqiang Huang: Advances in Clinical Immunotherapy for Lymphoma, Highlighting PD-1/PD-L1 Antibody Combination Therapies

In the realm of immunotherapy for lymphoma, PD-1/PD-L1 antibody combination therapies have emerged as a prominent area of research due to their precise modulation of the immune response. These therapies hold immense potential for enhancing efficacy and ensuring safety, providing lymphoma patients with more treatment options and the possibility of improved quality of life and prognosis. At the recent "2024 Nanjing Lymphoma Forum," Dr.  Huiqiang Huang from the Sun Yat-sen University Cancer Center delivered an outstanding presentation titled "Advances in Immunotherapy for Lymphoma: Clinical Exploration of PD-1/PD-L1 Antibody Combination Therapies." Following the forum, "Oncology Frontier - Hematology Frontier" invited Dr.  Huang for an interview to share further insights on this topic.
Dr. Zhangyin Ming: TGF-β1 Released by Platelets Promotes Tumor Cell Autophagy, Mediates Epithelial-Mesenchymal Transition, and Tumor Metastasis

Dr. Zhangyin Ming: TGF-β1 Released by Platelets Promotes Tumor Cell Autophagy, Mediates Epithelial-Mesenchymal Transition, and Tumor Metastasis

From June 22 to June 26, 2024, the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference was successfully held in Bangkok, Thailand. At this year's conference, a study by Dr. Zhangyin Ming's team from the School of Basic Medicine, Tongji Hospital of Huazhong University of Science and Technology, explored "The Role of Platelets in Epithelial-Mesenchymal Transition (EMT) and Tumor Metastasis of Cancer Cells in Situ." "Oncology Frontier - Hematology Frontier" invited Dr. Zhangyin Ming to provide an in-depth analysis of the research content. Here is a detailed summary for our readers.
EHA Expert Interview | Dr. Sizhou Feng: Insights from Resistant Bacterial Colonization in Hematology Patients for Empirical Therapy

EHA Expert Interview | Dr. Sizhou Feng: Insights from Resistant Bacterial Colonization in Hematology Patients for Empirical Therapy

Patients undergoing hematopoietic stem cell transplantation and high-dose chemotherapy for hematological diseases have impaired immune function, making them highly susceptible to febrile neutropenia and colonization or infection with resistant bacteria. Prompt and accurate initiation of empirical therapy is crucial to improve patient outcomes. At the 2024 European Hematology Association (EHA) Annual Meeting, Dr. Sizhou Feng's team from the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, reported a study showing a high proportion of bloodstream infections caused by carbapenem-resistant Acinetobacter spp. (CRA) in hematology patients, with homology between bloodstream isolates and colonizing bacteria. This indicates the need to strengthen hospital infection control to reduce resistant bacterial colonization and to promptly initiate appropriate empirical antimicrobial therapy for suspected infections in patients colonized with resistant bacteria. "Oncology Frontier - Hematology Frontier" invited Dr. Sizhou Feng to introduce and interpret this research at the EHA meeting.
Epigenetic Changes and Chromatin Architecture in Lipid Metabolic Reprogramming During Trastuzumab Adaptation in HER2-Positive Breast Cancer

Epigenetic Changes and Chromatin Architecture in Lipid Metabolic Reprogramming During Trastuzumab Adaptation in HER2-Positive Breast Cancer

In a significant advancement in breast cancer research, Dr. Yongmei Yin and her team from The First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital published the article "Unveiling Alterations of Epigenetic Modifications and Chromatin Architecture Leading to Lipid Metabolic Reprogramming during the Evolutionary Trastuzumab Adaptation of HER2-Positive Breast Cancer" in Advanced Science on May, 2024. This pivotal study investigates the epigenetic and chromatin structural changes that lead to metabolic reprogramming during the development of trastuzumab resistance in HER2-positive breast cancer. HER2-positive breast cancer is characterized by the overexpression of the HER2 protein, which promotes the growth of cancer cells. Trastuzumab, a monoclonal antibody, targets the HER2 protein but is met with resistance in many patients over time. This study addresses the urgent need to understand the underlying mechanisms of trastuzumab resistance to improve treatment strategies.
Dr. Zefei Jiang：Neoadjuvant-Adjuvant Pertuzumab in HER2-Positive Early Breast Cancer: Final Analysis of the Randomized Phase III PEONY Trial

Dr. Zefei Jiang：Neoadjuvant-Adjuvant Pertuzumab in HER2-Positive Early Breast Cancer: Final Analysis of the Randomized Phase III PEONY Trial

Dr. Zefei Jiang from The Fifth Medical Center of  Chinese PLA General Hospital, along with his colleagues, published the groundbreaking article titled "Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial" in Nature Communications  on March 9, 2024. This pivotal research examines the long-term efficacy and safety of incorporating pertuzumab, a monoclonal antibody, into the treatment regimen for HER2-positive early and locally advanced breast cancer. HER2-positive breast cancer is characterized by the overexpression of the human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Pertuzumab targets the HER2 receptor, working synergistically with trastuzumab, another HER2-targeted therapy, to provide a more effective treatment approach.
Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation 2

Dr. Xiaoyu Zhu and Dr. Aijie Huang on the Efficacy and Safety of TPO Receptor Agonists for Treating Thrombocytopenia Post-Cord Blood Transplantation 2

At the 32nd International Society on Thrombosis and Haemostasis (ISTH 2024) conference, the research team led by Professor Xiaoyu Zhu and Dr. Aijie Huang from The First Affiliated Hospital of the University of Science and Technology of China (Anhui Provincial Hospital) garnered significant attention. Their study on the efficacy and safety of avatrombopag for treating thrombocytopenia following cord blood transplantation (UCBT) was selected for oral presentation (OC33.3), with Dr. Huang delivering the report. This study not only showcases the exceptional capabilities of Chinese research teams in hematology but also contributes valuable insights to the global hematology community. "Oncology Frontier - Hematology Frontier" had an exclusive interview with Dr. Aijie Huang to delve deeper into the research and discuss future plans in the field of UCBT.
BOC/BOA 2024 | Professor Shaohua Zhang: Treatment Strategies for Breast Cancer Patients Post-CDK4/6 Inhibitor Therapy

BOC/BOA 2024 | Professor Shaohua Zhang: Treatment Strategies for Breast Cancer Patients Post-CDK4/6 Inhibitor Therapy

The results of studies such as postMONARCH and Young-PEARL presented at the 2024 ASCO Annual Meeting have sparked a new round of discussions on treatment strategies for patients with HR+/HER2- advanced breast cancer. To gain deeper insights into the significance of these studies and their implications for clinical practice, Professor Shaohua Zhang from The Fifth Medical Center of PLA General Hospital provided a detailed analysis of the relevant research at the 2024 BOC/BOA Annual Meeting.
Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds

Professor Jianyun Nie: Discussing Consensus and Controversies in Breast Cancer Diagnosis and Treatment in the South of Colorful Clouds

The 8th Yunling Breast Cancer Summit Forum, hosted by the Yunnan Anti-Cancer Association and the China Medical Education Association and organized by Peking University Cancer Hospital Yunnan Hospital/Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University/Yunnan Cancer Center, Yunnan Breast Cancer Clinical Research Center, Yunnan Anti-Cancer Association Breast Cancer Professional Committee, Yunnan Medical Association Breast Cancer Professional Committee, and China Medical Education Association Breast Disease Professional Committee, will be held on July 14, 2024, in the beautiful spring city of Kunming. "Oncology Frontier" interviewed Professor Jianyun Nie, the chairman of the conference, to share the highlights of this event.
Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis

Professor Guojun Zhang: Towering Yunling Mountains, Gathering of Renowned Experts, and Highlighting the New Heights of Breast Cancer Diagnosis

From July 12th to 14th, the 2024 CACA Integrated Breast Cancer Conference and The 8th Yunling Breast Cancer Summit Forum were held in Kunming, Yunnan. "Oncology Frontier" invited Professor Guojun Zhang, the chairman of both conferences and the president of Yunnan Cancer Hospital, to introduce the conference highlights, the hot directions of translational medicine research in breast cancer, and the achievements of Yunnan Cancer Hospital in breast cancer discipline construction. He also shared his outlook on the application prospects of artificial intelligence in breast cancer.
BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development

BOC/BOA 2024 | Professor Meng Wu: Major Advances in Lymphoma Treatment Boost Precision Medicine Development

From July 5th to 7th, the highly anticipated 2024 Annual Progress Seminar in Clinical Oncology in China (BOC) and Best of ASCO 2024 China were grandly held in Guangzhou. This conference focused on the "2023 Annual Progress in Clinical Oncology in China" selected by CSCO, aiming to deeply analyze the latest research achievements in the field of oncology in China. Based on the actual situation of cancer incidence in the country, the conference specially invited authoritative experts in the field of oncology and carefully selected outstanding papers from the 2024 ASCO conference in various related fields for comprehensive and in-depth interpretation. During the conference, "Oncology Frontier - Hematology Frontier" had the honor to interview Professor Meng Wu from Peking University Cancer Hospital, who shared profound insights and unique academic perspectives on major research in the field of lymphoma.